Grönholm, Juha
Pagni, Philippe P.
Pham, Minh N.
Gibson, Claire B.
Macomber, Paul F.
Vela, José Luis
von Herrath, Matthias
Lenardo, Michael J.
Funding for this research was provided by:
Sigrid Juséliuksen Säätiö
Wellstat Immunotherapeutics Corp (CRADA C-087-2006 (2006-0203))
Wellstat Diagnostics, LLC (CRADA C-022-2006 (2006-0369))
Novo Nordisk
National Institute of Allergy and Infectious Diseases
Emil Aaltosen Säätiö
Article History
Received: 4 November 2016
Accepted: 20 March 2017
First Online: 28 April 2017
Data availability
: The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
: This research was supported by the Division of Intramural Research, NIAID, Clinical Center and National Human Genome Research Institute, NIH. JG was supported by a fellowship grant from the Sigrid Juselius Foundation and by a grant from the Emil Aaltonen Foundation. Wellstat Immunotherapeutics supported this research with Cooperative Research and Development Agreement (CRADA) C-087-2006 (2006-0203) and Wellstat Diagnostics with CRADA C-022-2006 (2006-0369)<b>.</b> The study was also funded in part by Novo Nordisk.
: MvH, JLV, PPP, CBG and MNP are employed or affiliated with Novo Nordisk. All other authors declare that there is no duality of interest associated with their contribution to this manuscript.
: JG, MvH, JLV, PPP and MJL designed the experiments. JG, JLV, PPP, MNP, PFM and CBG performed the experiments and analysed the results. JG, PPP, MNP, PFM and JLV drafted the manuscript. All authors performed critical analysis of the manuscript and approved the final version to be published. MJL is a guarantor of this study and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Free to read: This content has been made available to all.